Revvity to acquire Human Cell Design

Revvity to acquire Human Cell Design
Key deals this week: Merck, Day One Biopharmaceutical, ABN AMRO, Revvity, Centerspace and more
Revvity to acquire ACD/Labs
17.52BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NYSE
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US7140461093
CUSIP
714046109
Sector
Healthcare
Industry
Diagnostics & Research
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
75.05
PEG Ratio
0.73
Book Value
64.78
Dividend Share
0.28
Dividend Yield
0.18%
Earnings Share
2.02
Wall Street Target Price
147.53
EPS Estimate Current Year
5.35
EPS Estimate Next Year
5.89
EPS Estimate Current Quarter
1.2162
EPS Estimate Next Quarter
1.3111
Most Recent Quarter
-
Revenue TTM
2,911,811,072
Gross Profit TTM
1,600,784,000
EBITDA
875,832,000
Profit Margin
8.16%
Return On Assets TTM
2.37%
Return On Equity TTM
3.21%
Revenue Per Share TTM
25.771
Qtly Revenue Growth YOY
1.30%
Diluted Eps TTM
2.02
Qtly Earnings Growth YOY
1.20%
Trailing PE
75.05
Forward PE
26
Price Sales TTM
5.8096
Price Book MRQ
2.4235
Enterprise Value Revenue
6
Enterprise Value EBITDA
25
176.50
2.44%700.00
2.38%459.90
2.23%387.50
2.02%794.21
1.67%262.59
1.65%231.67
1.32%22.35
-3.50%669.85
-0.36%79.15
-0.20%